These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30197477)

  • 21. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
    Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
    Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
    Menges CW; Sementino E; Talarchek J; Xu J; Chernoff J; Peterson JR; Testa JR
    Mol Cancer Res; 2012 Sep; 10(9):1178-88. PubMed ID: 22798428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.
    Ansardamavandi A; Nikfarjam M; He H
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
    Dunne RF; Hezel AF
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil in the Pancreatic Tumor Microenvironment.
    Jin L; Kim HS; Shi J
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
    Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
    J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
    Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
    Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
    Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
    Azmi AS; Mohammad RM
    Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
    [No Abstract]   [Full Text] [Related]  

  • 31. KRAS mutation in pancreatic cancer.
    Luo J
    Semin Oncol; 2021 Feb; 48(1):10-18. PubMed ID: 33676749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
    Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
    Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity.
    Ma Y; Dumesny C; Dong L; Ang CS; Asadi K; Zhan Y; Nikfarjam M; He H
    Cell Commun Signal; 2024 May; 22(1):287. PubMed ID: 38797819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
    Wu A; Jiang X
    Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
    Moss DY; McCann C; Kerr EM
    Sci Signal; 2022 Oct; 15(756):eabj3490. PubMed ID: 36256706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.
    Tripathi P; Kumari R; Pathak R
    Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
    Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
    J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.